文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胶质母细胞瘤免疫治疗研究中的转化模型。

Translational Models in Glioma Immunotherapy Research.

机构信息

School of Medicine, Stanford University, Stanford, CA 94305, USA.

Department of Neurosurgery, Stanford University Medical Center, Stanford, CA 94304, USA.

出版信息

Curr Oncol. 2023 Jun 11;30(6):5704-5718. doi: 10.3390/curroncol30060428.

DOI:10.3390/curroncol30060428
PMID:37366911
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10296936/
Abstract

Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed features regarding glioma behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into the common preclinical models used in glioma immunology, discuss their advantages and disadvantages, and highlight examples of their utilization in translational research.

摘要

免疫疗法是治疗神经胶质瘤的一个有前途的治疗领域。然而，各种免疫治疗方式的临床试验并未显著提高患者的生存率。神经胶质瘤研究的临床前模型应忠实地反映神经胶质瘤行为、突变负荷、肿瘤与基质细胞相互作用以及免疫抑制机制等方面的临床观察特征。在这篇综述中，我们深入探讨了神经胶质瘤免疫学中常用的临床前模型，讨论了它们的优缺点，并强调了它们在转化研究中的应用实例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee05/10296936/907ac2279faf/curroncol-30-00428-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee05/10296936/907ac2279faf/curroncol-30-00428-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee05/10296936/907ac2279faf/curroncol-30-00428-g001.jpg

相似文献

[1]
Translational Models in Glioma Immunotherapy Research.

Curr Oncol. 2023-6-11

[2]
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.

Expert Opin Investig Drugs. 2020-7

[3]
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.

Curr Neurol Neurosci Rep. 2017-6

[4]
Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.

Int J Mol Sci. 2023-8-25

[5]
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.

Front Immunol. 2021

[6]
Glioma immunology and immunotherapy.

Neurosurgery. 2000-4

[7]
From Bench to Bedside, the Current State of Oncolytic Virotherapy in Pediatric Glioma.

Neurosurgery. 2020-11-16

[8]
Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.

Int Rev Immunol. 2022

[9]
Dendritic cell therapy of high-grade gliomas.

Brain Pathol. 2009-10

[10]
Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Viruses. 2021-7-2

引用本文的文献

[1]
Research progress on the role of dendritic cells in glioma during 1992-2024: a bibliometric analysis.

Front Immunol. 2025-6-20

[2]
Gasdermin E in glioblastoma -pyroptosis resistance and tumor-promoting functions.

Cell Death Discov. 2025-6-21

[3]
Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes.

Neurooncol Adv. 2024-12-7

[4]
Bridging the gap between tumor and disease: Innovating cancer and glioma models.

J Exp Med. 2025-1-6

[5]
Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.

Acta Neuropathol. 2024-11-27

[6]
Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma.

CNS Neurosci Ther. 2024-7

[7]
The tumour microenvironment, treatment resistance and recurrence in glioblastoma.

J Transl Med. 2024-6-6

本文引用的文献

[1]
Modeling glioblastoma complexity with organoids for personalized treatments.

Trends Mol Med. 2023-4

[2]
Humanized mouse models for immuno-oncology research.

Nat Rev Clin Oncol. 2023-3

[3]
Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.

J Immunother Cancer. 2022-12

[4]
The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.

Int J Mol Sci. 2022-9-1

[5]
Immune landscape of a genetically engineered murine model of glioma compared with human glioma.

JCI Insight. 2022-6-22

[6]
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.

Neuro Oncol. 2022-11-2

[7]
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.

Neuro Oncol. 2023-1-5

[8]
Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.

Neurosurg Focus. 2022-2

[9]
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy.

Sci Adv. 2021-10

[10]
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.

Neurooncol Adv. 2021-7-26

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索